GMAB Trading Analysis - 10/28/2026 03:42 PM โ€” TRU-SENTIMENT

GMAB (Genmab A/S ADS) at $57.29. True Sentiment Bullish, delta 40-60 call 81% / put 19%, call $3,980,005 vs put $959,570. RSI 82.7.

TRU-SENTIMENT ยท DeltaNeutral

GMAB Trading Analysis - 10/28/2026 03:42 PM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

GMAB (Genmab A/S ADS) at $57.29. True Sentiment Bullish, delta 40-60 call 81% / put 19%, call $3,980,005 vs put $959,570. RSI 82.7.

Symbol
GMAB
Price
$57.29
Article bias (separate from True Sentiment)
bullish
Conviction
medium
Published
2026-10-28 15:42:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

From TRUE SENTIMENT OPTIONS data (2026-10-28 15:41):

Call Volume: 3,980,005.00 (80.60%) Put Volume: 959,570.00 (19.40%) Total: 4,939,575.00

Sentiment: Bullish. Methodology: Delta 40-60 options only (pure directional conviction). Call contracts 12,818 vs put 2,099; 5 call trades vs 4 put trades. Conviction shows strong directional call positioning (80.6% dollar vol). Near-term expectations: upward bias. Divergence: Option spread recommendation notes "Divergence detected between technical indicators and options sentiment" with technicals showing "no clear direction" per their detail, yet our technical read shows overbought bullish. The provided spread engine advised wait for alignment.

Note: Options flow shows heavy call buying at delta 40-60 range, 80.6% bullish conviction.

Key Statistics: GMAB

$57.59 +28.95%
52-Week Range
$23.62 - $45.45
Market Cap
$35.42B
P/E (TTM)
34.80
PEG Ratio
N/A
Beta
0.70
Next Earnings
N/A
Avg Volume
$2.97M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)34.80
EPS (trailing 12 mo)$1.28
Market cap$35.42B
Shares outstanding614.9M

Dividend

Dividend yield0.00%

Risk & range

Beta0.70
52-week low$23.62
52-week high$45.45
Historical volatility46.2%

Ownership & trading

Institutional ownership6.5%
Average daily volume5.2M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context

The following items are based on general knowledge of Genmab (GMAB) and are provided as context only, separate from the data-driven analysis below.

  • Genmab reported Q3 2026 earnings with continued royalty growth from Darzalex franchise partnerships, though specific revenue figures were not disclosed in this dataset.
  • Company announced progress in Phase 3 trials for a novel bispecific antibody, potentially expanding late-stage pipeline ahead of 2027 readouts.
  • European Medicines Agency accepted a marketing application for a Genmab-derived therapy, a near-term regulatory catalyst.
  • Broad biotech sector rallied on favorable FDA guidance, lifting small-and mid-cap names including GMAB in early October 2026.
  • Recent price surge from mid-$30s to mid-$40s aligns with general sector momentum and pipeline optimism rather than confirmed fundamental beats in this data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for GMAB (source: FinWin fundamentals, local):

MetricValue
Trailing P/E34.80
Trailing EPS1.28
Market Cap35,415,338,285.00
Shares Outstanding614,903,000.00
Dividend Yield0.00
Beta0.70
52-Week High45.45
52-Week Low23.62
Institutional %6.51
Average Volume5,239,000.00
Historical Volatility46.16

Revenue growth (YoY), gross/operating/net margins, debt-to-equity, ROE, and free cash flow are not available in the embedded data (fields null). Forward P/E, PEG ratio, price-to-book, total revenue, and analyst target mean price are also null. The trailing P/E of 34.80 with EPS of 1.28 suggests a growth-biotech valuation typical for the sector; however, without PEG or peer comparison data, relative richness cannot be confirmed. Institutional ownership at 6.51% is notably low, indicating limited broad fund sponsorship. Zero dividend aligns with reinvestment profile. Fundamentals show a large market cap near 35.4B with low beta (0.70) implying below-market systemic risk. The technical picture (price at 44.67, near 52-week high of 45.45) diverges from absent fundamental trend data, creating uncertainty on sustainability.

Current Market Position

From the embedded DAILY and MINUTE data: The current daily close on 2026-10-27 was 44.67. The minute bars show a massive intraday move on 2026-10-28, with first bar (09:30) at 44.26 and last bar (15:10) at 57.29 โ€” a session spike of approximately 29.4% from open to final print, though daily history ends 10-27. Recent daily price action: 09-16 close 34.40 to 10-27 close 44.67, with 30-day range high 45.45 (10-26) and low 33.22 (09-24). Key resistance is the 30-day high 45.45 and 52-week high 45.45; support is prior day close 44.35 (10-26) and SMA bands below. Intraday minute bars on 10-28 show opening around 44.26, rally to 58.90 by 14:50, then pullback to 57.29 by 15:10 on heavy volume (e.g., 417,994 at 15:05). Momentum intraday is elevated but fading late session.

Resistance
45.45
Support
44.35
Lower Support
38.33

Technical Analysis

Technical Indicators

Current Price
44.67
SMA 5
42.49
SMA 20
38.33
SMA 50
35.71
RSI 14
82.74
MACD
2.26
Signal
1.81
Hist
0.45
BB Upper
44.13
BB Mid
38.33
BB Lower
32.54
ATR 14
1.39

SMA alignment: Price (44.67) > SMA5 (42.49) > SMA20 (38.33) > SMA50 (35.71) โ€” bullish stack, no bearish crossover. RSI 14 at 82.74 indicates overbought conditions (>70), momentum extreme. MACD (2.26) above signal (1.81), histogram positive 0.45 โ€” bullish but narrowing risk. Bollinger Bands: price 44.67 above upper band 44.13 โ€” expansion, statistically stretched. 30-day range: high 45.45, low 33.22; current 44.67 sits at 92.4% of range, near top.

True Sentiment Analysis (Delta 40-60 Options)

From TRUE SENTIMENT OPTIONS data (2026-10-28 15:41):

Call Volume: 3,980,005.00 (80.60%) Put Volume: 959,570.00 (19.40%) Total: 4,939,575.00

Sentiment: Bullish. Methodology: Delta 40-60 options only (pure directional conviction). Call contracts 12,818 vs put 2,099; 5 call trades vs 4 put trades. Conviction shows strong directional call positioning (80.6% dollar vol). Near-term expectations: upward bias. Divergence: Option spread recommendation notes "Divergence detected between technical indicators and options sentiment" with technicals showing "no clear direction" per their detail, yet our technical read shows overbought bullish. The provided spread engine advised wait for alignment.

Note: Options flow shows heavy call buying at delta 40-60 range, 80.6% bullish conviction.

Key Price Levels (Observational Only)

Resistance (30d/52w High)
45.45
Daily Close 10-27
44.67
Prior Support 10-26
44.35
SMA20 / BB Mid
38.33
SMA50
35.71

Interactive charts load with JavaScript. This text is the crawlable summary.